Search - tctmd.com

Displaying 741 - 760 of 879

Sort: Relevancy | Date

News Conference News TCT 2012

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

October 31, 2012

Presentation TCT 2012

XIMA: A Prospective, Randomized Trial of Everolimus-Eluting Stents vs. Bare-Metal Stents in Octogenarians

Presenter: Adam de Belder

October 26, 2012

Presentation TCT 2012

Coronary Complication Spectacle: From Air Emboli to Dislodged Stents to No Reflow, Perforations, and More

Presenter: John Douglas Jr

October 26, 2012

News Conference News TCT 2012

TCT Career Achievement Award Goes to CV Pathologist Renu Virmani, MD

October 26, 2012

Presentation TCT 2012

Reflections on Coronary Stents: From Bare Metal to Drug-Eluting to Bioabsorbable: My Personal Delights and Dilemmas

Presenter: Antonio Colombo

October 26, 2012

News Conference News TCT 2012

No Excess Bleeding with EES vs. BMS in Octogenarians Despite Prolonged DAPT

October 26, 2012

Presentation TCT 2012

ISAR-DESIRE 3: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons vs. Paclitaxel-Eluting Stents vs. Balloon Angioplasty for Restenosis of Limus-Eluting Coronary Stents

Presenter: Robert Byrne

October 26, 2012

Presentation TCT 2012

Will Polymer-Free DES Be Safer Than Bare Metal Stents?

Presenter: Philip Urban

October 25, 2012

Presentation TCT 2012

TWENTE 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Zotarolimus-Eluting Stents

Presenter: Clemens von Birgelen

October 25, 2012

Presentation TCT 2012

RESET 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

Presenter: Ken Kozuma

October 25, 2012

Presentation TCT 2012

Long-Term Results of Bifurcation Stenting with Everolimus-eluting vs. Sirolimus-eluting Stents: The SEA-CORP BC Trials

Presenter: Francesco Burzotta

October 25, 2012

Presentation TCT 2012

When Is PCI Justified in Complex (Non-Left Main) Multivessel Disease with Current Drug-Eluting Stents?

Presenter: Dean Kereiakes

October 25, 2012

Presentation TCT 2012

SORT OUT IV 3-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

Presenter: Lisette Okkels Jensen

October 25, 2012

Presentation TCT 2012

LEADERS 5-Year: A Prospective, Randomized Trial of Bioabsorbable Polymer-based Biolimus-Eluting vs. Sirolimus-Eluting Stents

Presenter: Patrick Serruys

October 25, 2012

Presentation TCT 2012

EXAMINATION 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Bare Metal Stents in Patients with ST-Segment Elevation Myocardial Infarction

Presenter: Manel Sabate

October 25, 2012

Presentation TCT 2012

Case 3: A Complex Bifurcation with Two or More Stents(Culotte Stenting)

Presenter: John Ormiston

October 25, 2012

Presentation TCT 2012

Case 2: A Complex Bifurcation with Two Stents (T-Stenting)

Presenter: David Rizik

October 25, 2012

Presentation TCT 2012

One or Two Stents: And How to Avoid Complications

Presenter: Kenneth Chin

October 24, 2012

Presentation TCT 2012

ISAR-LEFT MAIN 2: A Prospective, Randomized Trial of Everolimus-Eluting vs. Zotarolimus-Eluting Stents in Patients with Unprotected Left Main Disease

Presenter: Julinda Mehilli

October 24, 2012

Presentation TCT 2012

Case Presentation 4: AUC and the Elephant in the Room: Unnecessary Stents

Presenter: Larry Dean

October 24, 2012

Advertisement

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

XIMA: A Prospective, Randomized Trial of Everolimus-Eluting Stents vs. Bare-Metal Stents in Octogenarians

Coronary Complication Spectacle: From Air Emboli to Dislodged Stents to No Reflow, Perforations, and More

TCT Career Achievement Award Goes to CV Pathologist Renu Virmani, MD

Reflections on Coronary Stents: From Bare Metal to Drug-Eluting to Bioabsorbable: My Personal Delights and Dilemmas

No Excess Bleeding with EES vs. BMS in Octogenarians Despite Prolonged DAPT

ISAR-DESIRE 3: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons vs. Paclitaxel-Eluting Stents vs. Balloon Angioplasty for Restenosis of Limus-Eluting Coronary Stents

Will Polymer-Free DES Be Safer Than Bare Metal Stents?

TWENTE 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Zotarolimus-Eluting Stents

RESET 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

Long-Term Results of Bifurcation Stenting with Everolimus-eluting vs. Sirolimus-eluting Stents: The SEA-CORP BC Trials

When Is PCI Justified in Complex (Non-Left Main) Multivessel Disease with Current Drug-Eluting Stents?

SORT OUT IV 3-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

LEADERS 5-Year: A Prospective, Randomized Trial of Bioabsorbable Polymer-based Biolimus-Eluting vs. Sirolimus-Eluting Stents

EXAMINATION 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Bare Metal Stents in Patients with ST-Segment Elevation Myocardial Infarction

Case 3: A Complex Bifurcation with Two or More Stents(Culotte Stenting)

Case 2: A Complex Bifurcation with Two Stents (T-Stenting)

One or Two Stents: And How to Avoid Complications

ISAR-LEFT MAIN 2: A Prospective, Randomized Trial of Everolimus-Eluting vs. Zotarolimus-Eluting Stents in Patients with Unprotected Left Main Disease

Case Presentation 4: AUC and the Elephant in the Room: Unnecessary Stents

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content